BioNTech to Acquire Biotheus to Boost Oncology Strategy
BioNTech SE (Nasdaq: BNTX, "BioNTech") and Biotheus ("Biotheus") today announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and development of novel antibodies to address unmet medical needs of patients with oncological or inflammatory diseases.
GlobalData on MSN10d
R3 Vascular secures investigational device exemption for PAD treatmentThe company has announced that its new investigational device exemption will be used to launch a pivotal trial of its ...
The MAQUET line of FUSION grafts merges ePTFE with PET to offer vascular surgeons the best of both materials: the easy handling of ePTFE and the minimal suture hole bleeding seen in knit polyester ...
StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th.
More than 18 years later, Best Vascular/Novoste continues to support and plans to expand the clinical uses of VBT. The ...
The global vascular patches market is projected to experience significant growth, with estimated sales reaching USD 160.3 million in 2024 and expected to climb to USD 256.2 million by 2034. This ...
Vascular surgeon Dr. Jaideep Das Gupta claimed the surgical room was one of the “most advanced in North America.” The ...
The death of the great British actor Timothy West at the age of 90 deprives the country of one of its most versatile and ...
The Vascular Ehlers-Danlos Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage ...
Stifel Nicolaus analyst Rick Wise maintained a Buy rating on Lemaitre Vascular (LMAT – Research Report) today and set a price target of ...
It's set elsewhere. Okay ... I think we're up to about 14% of our sales are now cardiac sales as opposed to vascular and still some interventional radiology and stuff like that.
The escalating demand for swift and reliable vascular access solutions is fueling the growth of the intraosseous infusion devices market, which is forecasted to achieve a CAGR of 6.9% over the next ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback